Geneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
Dubrovnik, 9 June 2016 – During the next two days, the key pharmaceutical industry leaders from the generic, biosimilar and value added medicines industries will meet in Dubrovnik to foster international partnership, cooperation and dialogue and discuss the most recent challenges of these industries for the future. With this year’s conference in Croatia, Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) celebrate their first joint event.
Brussels, June 3, 2016 – IGBA thanks the Agency’s for providing an opportunity to comment on the Agency’s Draft Guidance on Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643-0001). IGBA’s position is aligned with the key comments of the Biosimilar Medicines Group, a sector group of Medicines for Europe, which have been submitted separately.
- IGBA welcomes Productivity Commission Draft Report in Australia and supports immediate Australian patent reform
- IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal
- IGBA Files Recommendations for USTR 2016 Special 301 Review
- Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement